Ganoderma lucidum for the treatment of cardiovascular risk factors

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Klupp, Nerida L ^a   Chang, Dennis ^a   Hawke, Fiona ^b   Kiat, Hosen ^c   Grant, Suzanne J ^a   Bensoussan, Alan ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Cardiac Health Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GANODERMA LUCIDUM EXTRACT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

BIOSIS; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; CROSSOVER PROCEDURE; DATA BASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; GANODERMA LUCIDUM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMATION RETRIEVAL; INSULIN BLOOD LEVEL; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEAN ARTERIAL PRESSURE; MEDICAL LITERATURE; MEDLINE; OBESITY; PHASE 1 CLINICAL TRIAL; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCISEARCH; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 55049094254     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007259     Document Type: Review

References (20)

1. Chang 2000 Chang S-T, Miles P. Mushrooms: Cultivation, nutritional value, medicinal effect and environmental impact. 2nd Edition. Boca Raton, USA: CRC Press, 2000. [: 0-8493-1043-1]
2. Chen 2004 Chen J, Chen T. Chinese medical herbology and pharmacology. California: Art of Medicine Press, 2004:883-5.
3. Gao 2004a Gao Y, Chen G, Dai X, Ye J, Zhou S. A phase I/II study of Ling zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with coronary heart disease. International Journal of Medicinal Mushrooms 2004;6(4):327-34.
4. Gao 2004b Gao Y, Lan J, Dai X, Ye J, Zhou S. A phase I/II study of Ling zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with type II diabetes mellitus. International Journal of Medicinal Mushrooms 2004;6(1):33-9.
5. Higgins 2006 Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (updated September 2006). The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd, 2006, issue 4.
6. Hossain 2007 Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. New England Journal of Medicine 2007;356(3):213-5.
7. Huie 2004 Huie C, Di X. Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences 2004;812(1-2):241-57.
8. Jin 1996 Jin H, Zhang G, Cao X, Zhang M, Long J, Luo B, et al.Treatment of hypertension by Linzhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. Microcirculatory approach to Asian traditional medicine: Strategy for the scientific evaluation: selected proceedings from the 2nd Asian Congress for Microcirculation (ACM'95). Amsterdam; New York: Elsevier, 1996:131-8.
9. Kanmatsuse 1985 Kanmatsuse K, Kajiwara N, Hayashi K, Shimogaichi S, Fukinbara I, Ishikawa H, et al.Studies on Ganoderma lucidum. I. Efficacy against hypertension and side effects. Journal of the Pharmaceutical Society of Japan 1985;105(10):942-7.
10. Lakshmi 2003 Lakshmi B, Ajith T, Sheena N, Gunapalan N, Janardhanan K. Anti-peroxidative, anti-inflammatory, and antimutagenic activities of ethanol extract of the mycelium of Ganoderma lucidum occurring in South India. Teratogenesis, carcinogenesis, and mutagenesis 2003;23(Suppl 1):85-97.
11. Maxwell 2006 Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R. Method guidelines for Cochrane Musculoskeletal Group Systematic Reviews. Journal of Rheumatology 2006;33(11):2305-11.
12. McKenna 2002 McKenna D, Jones K, Hughes K. Reishi. Botanical medicines: The desk reference for major herbal supplements. 2nd Edition. Binghamton, New York: The Haworth Herbal Press, 2002:825-55.
13. Pearson 2003 Pearson T, Mensah G, Alexander R, Anderson J, Cannon R, Criqui M, et al.Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals for the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
14. Teow 1996 Teow S. Effective dosage of the extract of Ganoderma lucidum in the treatment of various ailments. In: Royse DJ editor(s). Mushroom biology and mushroom products. Pennsylvania: Pennsylvania State University, 1996.
15. Wachtel-Galor 2004a Wachtel-Galor S, Tomlinson B, Benzie I. Ganoderma lucidum ('Lingzhi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation. British Journal of Nutrition 2004;91(2):263-9.
16. Wachtel-Galor 2004b Wachtel-Galor S, Szeto Y, Tomlinson B, Benzie I. Ganoderma lucidum ('Lingzhi'): acute and short term biomarker response to supplementation. International Journal of Food Sciences and Nutrition 2004;55(1):75-83.
17. WHO 2005 World Health Organization (WHO) and US Centres for Disease Control and Prevention (CDC). In: Mackay J, Mensah G editor(s). The atlas of heart disease and stroke. Geneva: World Health Organisation, 2007.
18. Willard 1990 Willard, T. Reishi mushroom: Herb of spiritual potency and medical wonder. Issaquah, Washington: Sylvan Press, 1990.
19. Yang 2002 Yang B, Jeong S, Song C. Hypolipidemic effect of exo- and endo-biopolymers produced from submerged mycelial culture of Ganoderma lucidum in rats. Journal of Microbiology and Biotechnology 2002;12(6):872-7.
20. Zhang 2004 Zhang H, Lin Z. Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacologica Sinica 2004;25(2): 191-5.